Literature DB >> 18925456

Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.

Urban Hellman1, Flora Alarcon, Hans-Erik Lundgren, Ole B Suhr, Catherine Bonaiti-Pellié, Violaine Planté-Bordeneuve.   

Abstract

Transthyretin (TTR) familial amyloid polyneuropathies (FAP) are autosomal dominant devastating afflictions. They were first described in Portugal, later in Japan and Sweden and are now recognized worldwide. The TTR Val30Met mutation is the most common, and depending on the geographic origin, a wide variation in age at onset of the disease is observed. In Europe, northern Sweden is the second most prevalent area of the disease, and a late age of onset of 56 years has been reported. The present study aims to estimate the penetrance in TTR Val30Met Swedish families. Genealogical investigations, clinical data and genotyping were obtained in 77 TTR-Val30Met Swedish families. The penetrance in Val30Met carriers and variation within the endemic area, according to gender and transmitting parents were calculated by a newly developed bias-free method. The penetrance estimates were low, i.e. 1.7% and 22% at age 30 and 60 years, respectively, and far from complete (69%) by age 90 years. Differences between Piteå and Skellefteå regions were observed. Moreover, penetrance was significantly higher when the mutation was inherited from the mother than from the father. The low penetrance observed in TTR FAP kindreds and its variations is important information for the genetic counseling and treatment of Swedish FAP patients and their families.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925456      PMCID: PMC2738945          DOI: 10.1080/13506120802193720

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  21 in total

1.  Advanced glycation end product in familial amyloidotic polyneuropathy (FAP).

Authors:  N Nyhlin; Y Ando; R Nagai; O Suhr; M El Sahly; H Terazaki; T Yamashita; M Ando; S Horiuchi
Journal:  J Intern Med       Date:  2000-04       Impact factor: 8.989

2.  Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.

Authors:  V Planté-Bordeneuve; J Carayol; A Ferreira; D Adams; F Clerget-Darpoux; M Misrahi; G Said; C Bonaïti-Pellié
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

3.  Heart transplantation in a 68-year-old patient with senile systemic amyloidosis.

Authors:  Uwe Fuchs; Armin Zittermann; Ole Suhr; Gösta Holmgren; Gero Tenderich; Kazutomo Minami; Reiner Koerfer
Journal:  Am J Transplant       Date:  2005-05       Impact factor: 8.086

4.  Cure model analysis in cancer: an application to data from the Children's Cancer Group.

Authors:  Richard Sposto
Journal:  Stat Med       Date:  2002-01-30       Impact factor: 2.373

Review 5.  Transthyretin related familial amyloid polyneuropathy.

Authors:  V Planté-Bordeneuve; G Said
Journal:  Curr Opin Neurol       Date:  2000-10       Impact factor: 5.710

Review 6.  Transthyretin mutations in hyperthyroxinemia and amyloid diseases.

Authors:  M J Saraiva
Journal:  Hum Mutat       Date:  2001-06       Impact factor: 4.878

Review 7.  Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.

Authors:  Shu-ichi Ikeda; Masamitsu Nakazato; Yukio Ando; Gen Sobue
Journal:  Neurology       Date:  2002-04-09       Impact factor: 9.910

8.  Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins.

Authors:  G Holmgren; L Wikström; H-E Lundgren; O B Suhr
Journal:  J Intern Med       Date:  2004-11       Impact factor: 8.989

9.  Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis.

Authors:  U Drugge; R Andersson; F Chizari; M Danielsson; G Holmgren; O Sandgren; A Sousa
Journal:  J Med Genet       Date:  1993-05       Impact factor: 6.318

10.  Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences.

Authors:  G Holmgren; S Bergström; U Drugge; E Lundgren; C Nording-Sikström; O Sandgren; L Steen
Journal:  Clin Genet       Date:  1992-01       Impact factor: 4.438

View more
  49 in total

1.  Tafamidis.

Authors:  Gerard Said; Seden Grippon; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  [Hereditary cardiac amyloidosis with transthyretin mutations. A cause of sudden death ].

Authors:  C Edler; W Saeger; U Orth; C Braun; B Wulff; J Sperhake
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

Review 3.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

4.  Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype.

Authors:  Samih H Nasr; Surendra Dasari; John R Mills; Jason D Theis; Michael T Zimmermann; Rafael Fonseca; Julie A Vrana; Steven J Lester; Brooke M McLaughlin; Robert Gillespie; W Edward Highsmith; John J Lee; Angela Dispenzieri; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2017-01-03       Impact factor: 10.121

5.  Non-parametric estimation of survival in age-dependent genetic disease and application to the transthyretin-related hereditary amyloidosis.

Authors:  Flora Alarcon; Violaine Planté-Bordeneuve; Malin Olsson; Grégory Nuel
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

Review 6.  [Hereditary transthyretin amyloidosis].

Authors:  E Hund
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 7.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 8.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

Review 9.  Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.

Authors:  Philippe Kerschen; Violaine Planté-Bordeneuve
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

10.  A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.

Authors:  Malin Olsson; Nina Norgren; Konen Obayashi; Violaine Plante-Bordeneuve; Ole B Suhr; Kristina Cederquist; Jenni Jonasson
Journal:  BMC Med Genet       Date:  2010-09-14       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.